# A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

> **NCT00000798** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 32 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** HIV-1 Peptide Vaccine, Microparticulate Monovalent

## Key facts

- **NCT ID:** NCT00000798
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 32 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000798, "A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00000798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*